An upsurge in compliance focus, anti-bribery measures and a drive to greater transparency is leading pharma towards partners with demonstrable compliance capability and infrastructure. McCann Complete Health details this in an article featured on PM Live.
Compliance has always been a strategic imperative for pharma. However, while governance determining how industry communicates with healthcare stakeholders is well established, a sharper focus on ethics and corporate responsibility has emerged.
It is also a challenge that extends beyond individual pharmaceutical companies and into their diverse supplier base. It is a collective responsibility that requires a true partnership between client and its agencies, an understanding of increased pressures and an appreciation of the real-world variability in resourcing levels. Thus, pharma companies must identify partners that take compliance seriously and have the infrastructure, scale, and agility to respond to client needs.
“Marketing, procurement and compliance managers must identify partners that take compliance seriously and have the infrastructure, scale and agility to respond to clients’ compliance and ethics requirements.” ¬– Andrew Berrie, Chief Operations Officer, McCann Complete Medical